References

A review of Tenofovir Disoproxil Fumarate associated nephrotoxicity among People Living with HIV: Burden, risk factors and solutions

10.1016/j.cegh.2023.101462 · 2024 · External reference

Current trend in antiviral therapy for chronic hepatitis B

10.3390/v14020434 · 2022 · External reference

Hepatitis B virus treatment and hepatocellular carcinoma: Controversies and approaches to consensus

10.1159/000525518 · 2022 · External reference

Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection

10.1111/apt.17040 · 2022 · External reference

Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis of randomised control trials

10.1002/rmv.2216 · 2021 · External reference

Tenofovir-induced renal and bone toxicity: report of two cases and literature review

10.1590/s1678-9946202264010 · 2022 · External reference

Bone mineral content, growth, and renal health of infants with perinatal exposure to maternal dolutegravir versus efavirenz and tenofovir disoproxil fumarate versus tenofovir alafenamide: The randomized IMPAACT 2010 (VESTED) trial [Article

10.1097/qai.0000000000003656 · 2025 · External reference

Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study

10.3389/fendo.2023.1076739 · 2023 · External reference

Maternal and fetal vitamin D and their roles in mineral homeostasis and fetal bone development

10.1007/s40618-020-01387-2 · 2021 · External reference

Bone metabolism, bone mass, and bone structure during pregnancy and lactation: Normal physiology and pregnancy and lactation-associated osteoporosis

10.1016/j.ecl.2024.05.003 · 2024 · External reference

Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

10.1016/s2352-3018(23)00261-8 · 2023 · External reference

Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: A systematic review and meta-analysis

10.1093/cid/ciae288 · 2024 · External reference

Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B

10.1111/apt.14497 · 2018 · External reference

Phosphaturia in HIV-exposed uninfected neonates associated with maternal use of tenofovir disoproxil fumarate in late pregnancy [Article

10.1093/jpids/piae054 · 2024 · External reference

Comparative evaluation of adverse drug reactions for tenofovir alafenamide and tenofovir disoproxil fumarate using the FAERS Database: a disproportionality analysis

10.1080/14740338.2024.2391496 · 2025 · External reference

Biochemical markers of calcium and bone metabolism during and after lactation in Ugandan women with HIV on universal maternal antiretroviral therapy

10.1002/jbmr.4866 · 2023 · External reference

Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China [Article

10.1136/gutjnl-2020-322719 · 2022 · External reference

Effects of antiviral therapy with tenofovir disoproxil fumarate during pregnancy on bone metabolism of pregnant women and bone mineral density of newborns

2021 · External reference

In-utero exposure to tenofovir-containing pre-exposure prophylaxis and bone mineral content in HIV-unexposed infants in South Africa

10.1002/jia2.26379 · 2024 · External reference

Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B

10.1016/j.jhep.2023.12.001 · 2024 · External reference

Scoping studies: towards a methodological framework

10.1080/1364557032000119616 · 2005 · External reference

PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation

10.7326/m18-0850 · 2018 · External reference

Unresolved reference

External reference

Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi

10.1093/jac/dkw268 · 2016 · External reference

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial

10.1371/journal.pmed.1001217 · 2012 · External reference

Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children

10.1097/inf.0000000000000747 · 2015 · External reference

In utero tenofovir exposure is not associated with fetal long bone growth [Article

10.1093/cid/ciw159 · 2016 · External reference

Tenofovir disoproxil fumarate use during pregnancy and infant bone health: The Tenofovir in Pregnancy Pilot Study [Article

10.1097/inf.0000000000002152 · 2018 · External reference

Longitudinal comparison of bone, growth and biochemical markers in breastfed HIV-exposed uninfected and HIV-unexposed Ugandan children

10.1093/jbmr/zjag024 · 2026 · External reference

Bone age and mineral density assessments using plain roentgenograms in tenofovir-exposed infants in Malawi and Brazil enrolled in HIV Prevention Trials Network 057

10.1097/inf.0000000000001386 · 2017 · External reference

Maternal and infant bone mineral density 1 year after delivery in a randomized, controlled trial of maternal tenofovir disoproxil fumarate to prevent mother-to-child transmission of hepatitis B virus [Article

10.1093/cid/ciy982 · 2019 · External reference

Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy [Article

10.1016/j.ijid.2021.03.023 · 2021 · External reference

Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy [article

10.1093/cid/civ437 · 2015 · External reference

Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial

10.1097/qai.0000000000003218 · 2023 · External reference

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers [article

10.3851/imp1909 · 2011 · External reference

Tenofovir treatment during late pregnancy blocks the vertical transmission of HBV with no obvious impact on bone mineral density of infants via breast-feeding

10.16506/j.1009-6639.2020.01.007 · 2020 · External reference

Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate [article

10.1016/j.jhep.2020.01.021 · 2020 · External reference

Growth and neurodevelopment outcomes in HIV-, tenofovir-, and efavirenz-exposed breastfed infants in the PMTCT Option B+ program in Malawi

10.1097/qai.0000000000002515 · 2021 · External reference

Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial

10.1371/journal.pone.0246272 · 2021 · External reference

Influence of maternal use of tenofovir disoproxil fumarate or zidovudine in Vietnamese pregnant women with HIV on infant growth, renal function, and bone health [Article

10.1371/journal.pone.0250828 · 2021 · External reference

Tenofovir disoproxil fumarate/emtricitabine prophylaxis has no effect on bone mineral density and bone mineral content in African breastfeeding women receiving pre-exposure prophylaxis for HIV

10.1097/qai.0000000000003563 · 2025 · External reference

Markers of maternal bone and renal toxicity through 50 weeks postpartum: IMPAACT 2010 (VESTED) trial [Article

10.1097/qai.0000000000003478 · 2024 · External reference

Bone mineral density changes in breastfeeding women with HIV on antiretroviral therapy in Eastern and Southern Africa

10.1097/qad.0000000000004148 · 2025 · External reference

Milk calcium and phosphorus in Ugandan women with HIV on tenofovir-based antiretroviral therapy

10.1177/08903344221146472 · 2023 · External reference

Changes in bone mineral density during and after lactation in Ugandan women with HIV on tenofovir-based antiretroviral therapy

10.1002/jbmr.4121 · 2020 · External reference

Impact of tenofovir disoproxil fumarate use during pregnancy on maternal bone mineral density

10.1097/inf.0000000000003719 · 2022 · External reference

Safety of tenofovir disoproxil fumarate in pregnant women with HBV infection: An observation on renal functions and fetal growths

2022 · External reference

Recommendations for evaluation and management of bone disease in HIV

10.1093/cid/civ010 · 2015 · External reference

Gender and sex considerations in HIV and bone health

10.1097/coh.0000000000000780 · 2023 · External reference

Understanding HIV-exposed uninfected children: A narrative review

10.3390/v17030442 · 2025 · External reference

Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: Where are we now and where are we heading? [Review

10.1002/jia2.25426 · 2020 · External reference

Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone

10.3851/imp3269 · 2018 · External reference

Bone density changes in young women in Uganda using tenofovir-based HIV preexposure prophylaxis and depot medroxyprogesterone acetate contraception [Article

10.1097/qad.0000000000004029 · 2025 · External reference

Effect of antiretroviral therapy on bone and renal health in young adults infected with HIV in early life

10.1210/jc.2017-00197 · 2017 · External reference

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

10.1007/s001980200108 · 2002 · External reference

Antiseizure medications and bone health

10.1007/s40120-025-00805-y · 2025 · External reference

Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review

10.1590/s0004-27302010000200008 · 2010 · External reference

Vitamin D deficiency

10.1056/nejmra070553 · 2007 · External reference

Effect of carbamazepine and valproate on bone mineral density

10.1016/s0022-3476(95)70304-7 · 1995 · External reference

Nutritional rickets: deficiency of vitamin D, calcium, or both

10.1093/ajcn/80.6.1725s · 2004 · External reference

Effects of Tenofovir Disoproxil Fumarate on bone quality beyond bone density-a scoping review of the literature

10.3390/ph17020146 · 2024 · External reference

Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate

10.1097/qad.0000000000001780 · 2018 · External reference

Bone density, microarchitecture, and tissue quality after long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine

10.1097/qai.0000000000001396 · 2017 · External reference

Deficits in bone strength, density and microarchitecture in women living with HIV: A cross-sectional HR-pQCT study

10.1016/j.bone.2020.115509 · 2020 · External reference

Bone quality beyond DXA in people living with HIV: A systematic review of HR-pQCT, TBS, microindentation, and vertebral fractures

10.3390/jcm14217669 · 2025 · External reference

The role of vitamin D and vitamin D binding protein in chronic liver diseases

10.3390/ijms231810705 · 2022 · External reference

Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology [review

10.3389/fendo.2023.1161402 · 2023 · External reference

Osteoporosis in patients with chronic liver disease: pathogenesis, diagnosis and treatment

2023 · External reference

The impact of human immunodeficiency virus and menopause on bone mineral density: A longitudinal study of urban-dwelling South African women

10.1002/jbmr.4765 · 2023 · External reference